As long as Novo Nordisk continues to deliver on the lofty expectations that investors have for their new GLP-1 drugs, NVO shares should continue to book nice gains. Watch this week’s video to see how we are looking to play the current setup for Novo Nordisk.

Want a glimpse at which trades I am exploring each week? Click here to check it out.

As a key part of Chuck’s Optioneering Team, I work closely with Chuck throughout the week to review various setups and we select one we feel is ripe for a favorable move. Keep an eye on your Inbox for more insight to help you navigate the markets.

Thank you,

Blane Markham


Hughes Optioneering Team